Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation

Glycoconjugate Journal

Volumn 33, Issue 3, 2016, Pages 417-433

  Thaysen Andersen, M ^a   Chertova, E ^b   Bergamaschi, C ^c   Moh, E S X ^a   Chertov, O ^b   Roser, J ^b   Sowder, R ^b   Bear, J ^c   Lifson, J ^b   Packer, N H ^a   Felber, B K ^c   Pavlakis, G N ^c  

^a MACQUARIE UNIVERSITY   (Australia)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Glycoprotein; IL 15; IL 15R ; LC MS MS; N glycosylation; O glycosylation

Indexed keywords

ASPARAGINE; ASPARAGINE 107; ASPARAGINE 112; ASPARAGINE 71; ASPARAGINE 79; GLYCAN; GLYCOPEPTIDE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR ALPHA; MONOSACCHARIDE; POLYPEPTIDE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; IL15 PROTEIN, HUMAN; IL15RA PROTEIN, HUMAN; N ACETYLGLUCOSAMINE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DEAMINATION; FUCOSYLATION; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LYMPHOCYTE; MASS SPECTROMETRY; MOBILIZATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPRODUCIBILITY; SOLID PHASE EXTRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; HEK293 CELL LINE; HUMAN; METABOLISM; PROTEIN PROCESSING;

ACETYLGLUCOSAMINE; GLYCOSYLATION; HEK293 CELLS; HUMANS; INTERLEUKIN-15; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERLEUKIN-15; RECOMBINANT PROTEINS;

EID: 84975709022     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-015-9627-1     Document Type: Article

References (70)

1. Ma A., Koka R., Burkett P.: Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24, 657–679 (2006). doi:10.1146/annurev.immunol.24.021605.090727
2. Berard M., Brandt K., Bulfone-Paus S., Tough D.F.: IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 170(10), 5018–5026 (2003)
3. Burton J.D., Bamford R.N., Peters C., Grant A.J., Kurys G., Goldman C.K., Brennan J., Roessler E., Waldmann T.A.: A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. U. S. A. 91(11), 4935–4939 (1994)
4. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., Anderson D., Eisenmann J., Grabstein K., Caligiuri M.A.: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180(4), 1395–1403 (1994)
5. Zhang X., Sun S., Hwang I., Tough D.F., Sprent J.: Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 8(5), 591–599 (1998)
6. Dubois S., Patel H.J., Zhang M., Waldmann T.A., Muller J.R.: Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J. Immunol. 180(4), 2099–2106 (2008)
7. Epardaud M., Elpek K.G., Rubinstein M.P., Yonekura A.R., Bellemare-Pelletier A., Bronson R., Hamerman J.A., Goldrath A.W., Turley S.J.: Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68(8), 2972–2983 (2008). doi:10.1158/0008-5472.CAN-08-0045
8. Stoklasek T.A., Schluns K.S., Lefrancois L.: Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177(9), 6072–6080 (2006)
9. Cheever M.A.: Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357–368 (2008). doi:10.1111/j.1600-065X.2008.00604.x
10. Croce M., Orengo A.M., Azzarone B., Ferrini S.: Immunotherapeutic applications of IL-15. Immunotherapy. 4(9), 957–969 (2012). doi:10.2217/imt.12.92
11. Bergamaschi C., Kulkarni V., Rosati M., Alicea C., Jalah R., Chen S., Bear J., Sardesai N.Y., Valentin A., Felber B.K., Pavlakis G.N.: Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther. 22(1), 76–86 (2015). doi:10.1038/gt.2014.84
12. Dubois S., Mariner J., Waldmann T.A., Tagaya Y.: IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 17(5), 537–547 (2002)
13. Sandau M.M., Schluns K.S., Lefrancois L., Jameson S.C.: Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J. Immunol. 173(11), 6537–6541 (2004)
14. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., Ma A.: Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200(7), 825–834 (2004). doi:10.1084/jem.20041389
15. Koka R., Burkett P.R., Chien M., Chai S., Chan F., Lodolce J.P., Boone D.L., Ma A.: Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J. Exp. Med. 197(8), 977–984 (2003). doi:10.1084/jem.20021836
16. Bergamaschi C., Jalah R., Kulkarni V., Rosati M., Zhang G.M., Alicea C., Zolotukhin A.S., Felber B.K., Pavlakis G.N.: Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J. Immunol. 183(5), 3064–3072 (2009). doi:10.4049/jimmunol.0900693
17. Bergamaschi C., Rosati M., Jalah R., Valentin A., Kulkarni V., Alicea C., Zhang G.M., Patel V., Felber B.K., Pavlakis G.N.: Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J. Biol. Chem. 283(7), 4189–4199 (2008). doi:10.1074/jbc.M705725200
18. Bergamaschi C., Bear J., Rosati M., Beach R.K., Alicea C., Sowder R., Chertova E., Rosenberg S.A., Felber B.K., Pavlakis G.N.: Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood. 120(1), e1–e8 (2012). doi:10.1182/blood-2011-10-384362
19. Chertova, E., Bergamaschi, C., Chertov, O., Sowder, R., Bear, J., Roser, J.D., Beach, R.K., Lifson, J.D., Felber, B.K., Pavlakis, G.N.: Characterization and favorable in vivo properties of heterodimeric soluble IL-15 IL-15Ralpha cytokine compared to IL-15 monomer. J. Biol. Chem. 288(25), 18093–18103 (2013). doi:10.1074/jbc.M113.461756
20. Chamorey A.L., Magne N., Pivot X., Milano G.: Impact of glycosylation on the effect of cytokines A special focus on oncology. Eur. Cytokine Netw. 13(2), 154–160 (2002)
21. Sola R.J., Griebenow K.: Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98(4), 1223–1245 (2009). doi:10.1002/jps.21504
22. Dissing-Olesen L., Thaysen-Andersen M., Meldgaard M., Hojrup P., Finsen B.: The function of the human interferon-beta 1a glycan determined in vivo. J. Pharmacol. Exp. Ther. 326(1), 338–347 (2008). doi:10.1124/jpet.108.138263
23. Beq S., Rozlan S., Gautier D., Parker R., Mersseman V., Schilte C., Assouline B., Rance I., Lavedan P., Morre M., Cheynier R.: Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood. 114(4), 816–825 (2009). doi:10.1182/blood-2008-11-191288
24. Takeuchi M., Kobata A.: Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology. 1(4), 337–346 (1991)
25. Jensen P.H., Karlsson N.G., Kolarich D., Packer N.H.: Structural analysis of N- and O-glycans released from glycoproteins. Nat. Protoc. 7(7), 1299–1310 (2012). doi:10.1038/nprot.2012.063
26. Thaysen-Andersen M., Thogersen I.B., Lademann U., Offenberg H., Giessing A.M., Enghild J.J., Nielsen H.J., Brunner N., Hojrup P.: Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases-1. Biochim. Biophys. Acta. 1784(3), 455–463 (2008). doi:10.1016/j.bbapap.2007.12.007
27. Mysling S., Palmisano G., Hojrup P., Thaysen-Andersen M.: Utilizing ion-pairing hydrophilic interaction chromatography solid phase extraction for efficient glycopeptide enrichment in glycoproteomics. Anal. Chem. 82(13), 5598–5609 (2010). doi:10.1021/ac100530w
28. Sethi M.K., Kim H., Park C.K., Baker M.S., Paik Y.K., Packer N.H., Hancock W.S., Fanayan S., Thaysen-Andersen M.: In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. Glycobiology. (2015). doi:10.1093/glycob/cwv042
29. Venkatakrishnan V., Thaysen-Andersen M., Chen S.C., Nevalainen H., Packer N.H.: Cystic fibrosis and bacterial colonization define the sputum N-glycosylation phenotype. Glycobiology. 25(1), 88–100 (2015). doi:10.1093/glycob/cwu092
30. Leymarie N., Griffin P.J., Jonscher K., Kolarich D., Orlando R., McComb M., Zaia J., Aguilan J., Alley W.R., Altmann F., Ball L.E., Basumallick L., Bazemore-Walker C.R., Behnken H., Blank M.A., Brown K.J., Bunz S.C., Cairo C.W., Cipollo J.F., Daneshfar R., Desaire H., Drake R.R., Go E.P., Goldman R., Gruber C., Halim A., Hathout Y., Hensbergen P.J., Horn D.M., Hurum D., Jabs W., Larson G., Ly M., Mann B.F., Marx K., Mechref Y., Meyer B., Moginger U., Neusubeta C., Nilsson J., Novotny M.V., Nyalwidhe J.O., Packer N.H., Pompach P., Reiz B., Resemann A., Rohrer J.S., Ruthenbeck A., Sanda M., Schulz J.M., Schweiger-Hufnagel U., Sihlbom C., Song E., Staples G.O., Suckau D., Tang H., Thaysen-Andersen M., Viner R.I., An Y., Valmu L., Wada Y., Watson M., Windwarder M., Whittal R., Wuhrer M., Zhu Y., Zou C.: Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol. Cell. Proteomics. 12(10), 2935–2951 (2013). doi:10.1074/mcp.M113.030643
31. Sumer-Bayraktar Z., Nguyen-Khuong T., Jayo R., Chen D.D., Ali S., Packer N.H., Thaysen-Andersen M.: Micro- and macroheterogeneity of N-glycosylation yields size and charge isoforms of human sex hormone binding globulin circulating in serum. Proteomics. 12(22), 3315–3327 (2012). doi:10.1002/pmic.201200354
32. Sumer-Bayraktar Z., Kolarich D., Campbell M.P., Ali S., Packer N.H., Thaysen-Andersen M.: N-glycans modulate the function of human corticosteroid-binding globulin. Mol. Cell. Proteomics. 10(8), M111 009100 (2011). doi:10.1074/mcp.M111.009100
33. Stavenhagen K., Hinneburg H., Thaysen-Andersen M., Hartmann L., Varon Silva D., Fuchser J., Kaspar S., Rapp E., Seeberger P.H., Kolarich D.: Quantitative mapping of glycoprotein micro-heterogeneity and macro-heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides. J. Mass Spectrom. 48(6), 627–639 (2013). doi:10.1002/jms.3210
34. Ring A.M., Lin J.X., Feng D., Mitra S., Rickert M., Bowman G.R., Pande V.S., Li P., Moraga I., Spolski R., Ozkan E., Leonard W.J., Garcia K.C.: Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13(12), 1187–1195 (2012). doi:10.1038/ni.2449
35. Thaysen-Andersen M., Venkatakrishnan V., Loke I., Laurini C., Diestel S., Parker B.L., Packer N.H.: Human neutrophils secrete bioactive paucimannosidic proteins from azurophilic granules into pathogen-infected sputum. J. Biol. Chem. 290(14), 8789–8802 (2015). doi:10.1074/jbc.M114.631622
36. Thaysen-Andersen M., Wilkinson B.L., Payne R.J., Packer N.H.: Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS. Electrophoresis. 32(24), 3536–3545 (2011). doi:10.1002/elps.201100294
37. Zeck A., Pohlentz G., Schlothauer T., Peter-Katalinic J., Regula J.T.: Cell type-specific and site directed N-glycosylation pattern of FcgammaRIIIa. J. Proteome Res. 10(7), 3031–3039 (2011). doi:10.1021/pr1012653
38. Jalah R., Rosati M., Kulkarni V., Patel V., Bergamaschi C., Valentin A., Zhang G.M., Sidhu M.K., Eldridge J.H., Weiner D.B., Pavlakis G.N., Felber B.K.: Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol. 26(12), 827–840 (2007). doi:10.1089/dna.2007.0645
39. Kobayashi H., Dubois S., Sato N., Sabzevari H., Sakai Y., Waldmann T.A., Tagaya Y.: Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 105(2), 721–727 (2005). doi:10.1182/blood-2003-12-4187
40. Conlon K.C., Lugli E., Welles H.C., Rosenberg S.A., Fojo A.T., Morris J.C., Fleisher T.A., Dubois S.P., Perera L.P., Stewart D.M., Goldman C.K., Bryant B.R., Decker J.M., Chen J., Worthy T.A., Figg Sr. W.D., Peer C.J., Sneller M.C., Lane H.C., Yovandich J.L., Creekmore S.P., Roederer M., Waldmann T.A.: Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33(1), 74–82 (2015). doi:10.1200/JCO.2014.57.3329
41. Lugli E., Goldman C.K., Perera L.P., Smedley J., Pung R., Yovandich J.L., Creekmore S.P., Waldmann T.A., Roederer M.: Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood. 116(17), 3238–3248 (2010). doi:10.1182/blood-2010-03-275438
42. Waldmann T.A., Lugli E., Roederer M., Perera L.P., Smedley J.V., Macallister R.P., Goldman C.K., Bryant B.R., Decker J.M., Fleisher T.A., Lane H.C., Sneller M.C., Kurlander R.J., Kleiner D.E., Pletcher J.M., Figg W.D., Yovandich J.L., Creekmore S.P.: Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 117(18), 4787–4795 (2011). doi:10.1182/blood-2010-10-311456
43. Berger C., Berger M., Hackman R.C., Gough M., Elliott C., Jensen M.C., Riddell S.R.: Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 114(12), 2417–2426 (2009). doi:10.1182/blood-2008-12-189266
44. Rubinstein M.P., Kovar M., Purton J.F., Cho J.H., Boyman O., Surh C.D., Sprent J.: Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. U. S. A. 103(24), 9166–9171 (2006). doi:10.1073/pnas.0600240103
45. Loke I., Packer N.H., Thaysen-Andersen M.: Complementary LC-MS/MS-based N-glycan, N-glycopeptide, and intact N-glycoprotein profiling reveals unconventional Asn71-glycosylation of human neutrophil cathepsin G. Biomolecules. 5(3), 1832–1854 (2015). doi:10.3390/biom5031832
46. Rudd P.M., Dwek R.A.: Glycosylation: heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32(1), 1–100 (1997). doi:10.3109/10409239709085144
47. Thaysen-Andersen M., Packer N.H.: Site-specific glycoproteomics confirms that protein structure dictates formation of N-glycan type, core fucosylation and branching. Glycobiology. 22(11), 1440–1452 (2012). doi:10.1093/glycob/cws110
48. Lee L.Y., Lin C.H., Fanayan S., Packer N.H., Thaysen-Andersen M.: Differential site accessibility mechanistically explains subcellular-specific N-glycosylation determinants. Front. Immunol. 5, 404 (2014). doi:10.3389/fimmu.2014.00404
49. Yang X., Tao S., Orlando R., Brockhausen I., Kan F.W.: Structures and biosynthesis of the N- and O-glycans of recombinant human oviduct-specific glycoprotein expressed in human embryonic kidney cells. Carbohydr. Res. 358, 47–55 (2012). doi:10.1016/j.carres.2012.05.027
50. Harvey D.J., Baruah K., Scanlan C.N.: Application of negative ion MS/MS to the identification of N-glycans released from carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1). J. Mass Spectrom. 44(1), 50–60 (2009). doi:10.1002/jms.1470
51. Chitlaru T., Kronman C., Velan B., Shafferman A.: Overloading and removal of N-glycosylation targets on human acetylcholinesterase: effects on glycan composition and circulatory residence time. Biochem. J. 363(Pt 3), 619–631 (2002)
52. Chitlaru T., Kronman C., Zeevi M., Kam M., Harel A., Ordentlich A., Velan B., Shafferman A.: Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem. J. 336(Pt 3), 647–658 (1998)
53. Geoghegan K.F., Song X., Hoth L.R., Feng X., Shanker S., Quazi A., Luxenberg D.P., Wright J.F., Griffor M.C.: Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line. Protein Expr. Purif. 87(1), 27–34 (2013). doi:10.1016/j.pep.2012.09.013
54. Van den Nieuwenhof I.M., Koistinen H., Easton R.L., Koistinen R., Kamarainen M., Morris H.R., Van Die I., Seppala M., Dell A., Van den Eijnden D.H.: Recombinant glycodelin carrying the same type of glycan structures as contraceptive glycodelin-a can be produced in human kidney 293 cells but not in Chinese hamster ovary cells. Eur. J. Biochem. 267(15), 4753–4762 (2000)
55. Eggleton P., Haigh R., Winyard P.G.: Consequence of neo-antigenicity of the ‘altered self’. Rheumatology (Oxford). 47(5), 567–571 (2008). doi:10.1093/rheumatology/ken014
56. Weintraub S.J., Deverman B.E.: Chronoregulation by asparagine deamidation. Sci. STKE. 2007(409), re7 (2007). doi:10.1126/stke.4092007re7
57. Vlasak J., Bussat M.C., Wang S., Wagner-Rousset E., Schaefer M., Klinguer-Hamour C., Kirchmeier M., Corvaia N., Ionescu R., Beck A.: Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal. Biochem. 392(2), 145–154 (2009). doi:10.1016/j.ab.2009.05.043
58. Zhao R., Oxley D., Smith T.S., Follows G.A., Green A.R., Alexander D.R.: DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol. 5(1), e1 (2007). doi:10.1371/journal.pbio.0050001
59. Nellis, D.F., Michiel, D.F., Jiang, M.S., Esposito, D., Davis, R., Jiang, H., Korrell, A., Knapp, G.C. 4th., Lucernoni, L.E., Nelson, R.E., Pritt, E.M., Procter, L.V., Rogers, M., Sumpter, T.L., Vyas, V.V., Waybright, T.J., Yang, X., Zheng, A.M., Yovandich, J.L., Gilly, J.A., Mitra, G., Zhu, J.: Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77. Pharm. Res. 29(3), 722–738 (2012). doi:10.1007/s11095-011-0597-0
60. Robinson N.E., Robinson Z.W., Robinson B.R., Robinson A.L., Robinson J.A., Robinson M.L., Robinson A.B.: Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J. Pept. Res. 63(5), 426–436 (2004). doi:10.1111/j.1399-3011.2004.00151.x
61. Takahashi M., Kuroki Y., Ohtsubo K., Taniguchi N.: Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr. Res. 344(12), 1387–1390 (2009). doi:10.1016/j.carres.2009.04.031
62. Tran D.T., Ten Hagen K.G.: Mucin-type O-glycosylation during development. J. Biol. Chem. 288(10), 6921–6929 (2013). doi:10.1074/jbc.R112.418558
63. Bennett E.P., Mandel U., Clausen H., Gerken T.A., Fritz T.A., Tabak L.A.: Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 22(6), 736–756 (2012). doi:10.1093/glycob/cwr182
64. Steentoft C., Vakhrushev S.Y., Joshi H.J., Kong Y., Vester-Christensen M.B., Schjoldager K.T., Lavrsen K., Dabelsteen S., Pedersen N.B., Marcos-Silva L., Gupta R., Bennett E.P., Mandel U., Brunak S., Wandall H.H., Levery S.B., Clausen H.: Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 32(10), 1478–1488 (2013). doi:10.1038/emboj.2013.79
65. Diswall M., Angstrom J., Karlsson H., Phelps C.J., Ayares D., Teneberg S., Breimer M.E.: Structural characterization of alpha1,3-galactosyltransferase knockout pig heart and kidney glycolipids and their reactivity with human and baboon antibodies. Xenotransplantation. 17(1), 48–60 (2010). doi:10.1111/j.1399-3089.2009.00564.x
66. Galili U.: The alpha-gal epitope and the anti-gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell Biol. 83(6), 674–686 (2005). doi:10.1111/j.1440-1711.2005.01366.x
67. Bosques C.J., Collins B.E., Meador 3rd J.W., Sarvaiya H., Murphy J.L., Dellorusso G., Bulik D.A., Hsu I.H., Washburn N., Sipsey S.F., Myette J.R., Raman R., Shriver Z., Sasisekharan R., Venkataraman G.: Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat. Biotechnol. 28(11), 1153–1156 (2010). doi:10.1038/nbt1110-1153
68. Yoo E.M., Chintalacharuvu K.R., Penichet M.L., Morrison S.L.: Myeloma expression systems. J. Immunol. Methods. 261(1–2), 1–20 (2002)
69. Baker K.N., Rendall M.H., Hills A.E., Hoare M., Freedman R.B., James D.C.: Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol. Bioeng. 73(3), 188–202 (2001)
70. Eisenman J., Ahdieh M., Beers C., Brasel K., Kennedy M.K., Le T., Bonnert T.P., Paxton R.J., Park L.S.: Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine. 20(3), 121–129 (2002)